ReviewJournal of human genetics2013
Pharmacogenetics of warfarin: challenges and opportunities.
Review in Journal of human genetics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 4 syntheses or guidelines pooled it, 119 citations in OpenAlex.
- Different antithrombotic strategies to prevent cardiovascular complications in Kawasaki patients: a systematic review and meta-analysis.BMC pediatrics · 2024Pooled it
- Bleeding complications in patients on warfarin undergoing joint injection/aspiration: systematic review and meta-analysis.Rheumatology international · 2023Pooled it
- Warfarin dosing algorithms: A systematic review.British journal of clinical pharmacology · 2021Pooled it
- Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis.Clinical pharmacology and therapeutics · 2020Pooled it
- Cluster-based psychological phenotyping and differences in anxiety treatment outcomes.Scientific reports · 2023Trial
- Genotype-Guided Dosing of Warfarin in Chinese Adults: A Multicenter Randomized Clinical Trial.Circulation. Genomic and precision medicine · 2020Trial
- Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study.BMC medicine · 2019Trial
- Coumarin Conjugation as an Albumin-Binding Strategy to Modulate the Pharmacokinetics of FAPI Radiotracers.ACS omega · 2026Article
- Treatment Stability of Warfarin and Acenocoumarol in Patients With Mechanical Heart Valves and Atrial Fibrillation: A One-Year Cohort Study.Acta medica academica · 2026Article
- Knowledgeable Language Models as Black-Box Optimizers for Personalized Medicine.... International Conference on Learning Representations · 2026Article
- Comparison of CYP2C9 activity between Ethiopian and non-Ethiopian Jews: an interethnic study of (Frontiers in pharmacology · 2026Article
- Anticoagulation Therapies and microRNAs in Heart Failure.Biomolecules · 2025Review
- Analysis of Personalized Cardiovascular Drug Therapy: From Monitoring Technologies to Data Integration and Future Perspectives.Biosensors · 2025Review
- Conceptual frameworks for the integration of genetic and social epidemiology in complex diseases.Global epidemiology · 2024Article
- Review
- QPGx-CARES: Qatar pharmacogenetics clinical applications and research enhancement strategies.Clinical and translational science · 2024Review
- Warfarin and Polypharmacy Challenges in Sudan: Drug Interactions in Patient Cohort.Integrated pharmacy research & practice · 2024Article
- Optimisation of warfarin-dosing algorithms for Han Chinese patients with CYP2C9*13 variants.European journal of clinical pharmacology · 2023Article
- Evaluation of a warfarin dosing algorithm including CYP2C9, VKORC1, and CYP4F2 polymorphisms and non-genetic determinants for the Iranian population.Pharmacological reports : PR · 2023Article
- Evaluation of supervised machine learning algorithms in predicting the poor anticoagulation control and stable weekly doses of warfarin.International journal of clinical pharmacy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Since the introduction in the 1950s, warfarin has become the commonly used oral anticoagulant for the prevention of thromboembolism in patients with deep vein thrombosis, atrial fibrillation or prosthetic heart valve replacement. Warfarin is highly efficacious; however, achieving the desired anticoagulation is difficult because of its narrow therapeutic window and highly variable dose response among individuals. Bleeding is often associated with overdose of warfarin. There is overwhelming evidence that an individual's warfarin maintenance is associated with clinical factors and genetic variations, most notably polymorphisms in cytochrome P450 2C9 and vitamin K epoxide reductase subunit 1. Numerous dose-prediction algorithms incorporating both genetic and clinical factors have been developed and tested clinically. However, results from major clinical trials are not available yet. This review aims to provide an overview of the field of warfarin which includes information about the drug, genetics of warfarin dose requirements, dosing algorithms developed and the challenges for the clinical implementation of warfarin pharmacogenetics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.